Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation

por Boykin, C, Zhang, G, Chen, Y-H, Zhang, R-W, Fan, X-E, Yang, W-M, Lu, Q
Publicado 2011

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation

por Boykin, C, Zhang, G, Chen, Y-H, Zhang, R-W, Fan, X-E, Yang, W-M, Lu, Q
Publicado 2012

A multi-center, controlled, randomized, open-label clinical study of levofloxacin for preventing infection during the perioperative period of ultrasound-guided transrectal prostate...

por Qiao, L.-D., Chen, S., Wang, X.-F., Yang, W.-M., Niu, Y.-J., Kong, C.-Z., Tang, W., Gao, X.-F., Shi, B.-K., Na, Y.-Q., Zhang, X.-D., Wang, J.-Y., Zhang, Y., Chen, Z.
Publicado 2016